{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:58:06Z","timestamp":1791561486061,"version":"4.3.4"},"reference-count":18,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Epilepsia Open"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:label\/>\n                    <jats:p>\n                      Migraine and epilepsy frequently coexist, but evidence on the safety of calcitonin gene\u2010related peptide (CGRP)\u2010targeting therapies in people with epilepsy is lacking. We evaluated long\u2010term migraine and epilepsy outcomes in a real\u2010world multicenter retrospective cohort of adults with comorbid migraine and epilepsy treated with anti\u2010CGRP monoclonal antibodies or gepants while on stable antiseizure medications. Eleven patients were included in the final analysis, all female, with a mean age of 34.7\u2009\u00b1\u200912.2\u2009years. At baseline, mean monthly headache days (MHDs) were 18.5\u2009\u00b1\u20097.8, with 54.5% episodic migraine and 45.5% chronic migraine; 72.7% of patients had drug\u2010resistant epilepsy, and baseline mean monthly seizure frequency was 0.75. Mean MHDs decreased to 7.6\u2009\u00b1\u20095.5 at 24\u2009weeks and to 5.4\u2009\u00b1\u20093.2 at 52\u2009weeks (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). At week 24, 90% of patients achieved a \u226550% reduction in MHDs, which was maintained at week 52; \u226575% response increased from 10% at week 24 to 20% at week 52, and 10% achieved migraine freedom at 1\u2009year; MIDAS and HIT6 scores decreased significantly from baseline to both 24 and 52\u2009weeks (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Acute medication days and intake were reduced by over 85% at the end of the study. Seizure frequency did not increase during follow\u2010up and showed a non\u2010significant numerical reduction to 0.40 monthly seizures at 52\u2009weeks (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.423). No seizure exacerbations or treatment\u2010related adverse events were observed. This study provides preliminary, long\u2010term observations suggesting that anti\u2010CGRP therapies may be effective for migraine prevention in patients with comorbid epilepsy. No adverse events or apparent worsening of seizure frequency were observed during the 52\u2010week follow\u2010up. These findings require confirmation in larger, prospective controlled studies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Plain Language Summary<\/jats:title>\n                    <jats:p>Migraine and epilepsy often occur together, but information on CGRP\u2010targeting migraine medicines in people with epilepsy is limited. We reviewed records from 11 women with both conditions over 1\u2009year. Headache, migraine\u2010related disability, and use of medicines for attacks decreased. Among 10 women with complete migraine follow\u2010up, nine had at least half as many headache days at both 6\u2009months and 1\u2009year. No worsening of seizures or treatment\u2010related side effects was reported. These findings are encouraging, but this small study without a comparison group cannot establish safety or prove treatment benefit.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/epi4.70364","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:42:36Z","timestamp":1791560556000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Preliminary evidence of long\u2010term safety and effectiveness of anti\u2010\n                    <scp>CGRP<\/scp>\n                    drugs for migraine prevention in people with comorbid epilepsy: A 52\u2010week follow\u2010up retrospective study"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6016-3141","authenticated-orcid":false,"given":"Marina","family":"Romozzi","sequence":"first","affiliation":[{"name":"Dipartimento Universitario di Neuroscienze Universit\u00e0 Cattolica del Sacro Cuore  Rome Italy"},{"name":"Neurologia, Dipartimento di Neuroscienze, Organi di Senso e Torace Fondazione Policlinico Universitario Agostino Gemelli IRCCS  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Burgalassi","sequence":"additional","affiliation":[{"name":"Headache Center and Clinical Pharmacology Unit AOU Careggi  Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ceriello","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Mental Health and Sensory Organs (NESMOS) Sapienza University of Rome  Rome Italy"},{"name":"Neurology Unit Sant'andrea University Hospital  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Martino","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Mental Health and Sensory Organs (NESMOS) Sapienza University of Rome  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8324-4371","authenticated-orcid":false,"given":"Giuliano","family":"Sette","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Mental Health and Sensory Organs (NESMOS) Sapienza University of Rome  Rome Italy"},{"name":"Neurology Unit Sant'andrea University Hospital  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Pistoia","sequence":"additional","affiliation":[{"name":"Department of Biotechnological and Applied Clinical Sciences University of L'aquila  L'Aquila Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Placidi","sequence":"additional","affiliation":[{"name":"Neurology Unit, Department of Systems Medicine Tor Vergata University  Rome Italy"},{"name":"IRCCS Neuromed  Pozzilli Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Centonze","sequence":"additional","affiliation":[{"name":"Neurology Unit, Department of Systems Medicine Tor Vergata University  Rome Italy"},{"name":"IRCCS Neuromed  Pozzilli Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Pani","sequence":"additional","affiliation":[{"name":"Department of Biomedical, Metabolic and Neural Sciences University of Modena and Reggio Emilia  Modena Italy"},{"name":"Department of Psychiatry and Behavioral Sciences University of Miami  Miami Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Canonichesi","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Telematica San Raffaele di Roma  Rome Italy"},{"name":"San Raffaele Sulmona  L'Aquila Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catello","family":"Vollono","sequence":"additional","affiliation":[{"name":"Dipartimento Universitario di Neuroscienze Universit\u00e0 Cattolica del Sacro Cuore  Rome Italy"},{"name":"Neurologia, Dipartimento di Neuroscienze, Organi di Senso e Torace Fondazione Policlinico Universitario Agostino Gemelli IRCCS  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Calabresi","sequence":"additional","affiliation":[{"name":"Dipartimento Universitario di Neuroscienze Universit\u00e0 Cattolica del Sacro Cuore  Rome Italy"},{"name":"Neurologia, Dipartimento di Neuroscienze, Organi di Senso e Torace Fondazione Policlinico Universitario Agostino Gemelli IRCCS  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Albanese","sequence":"additional","affiliation":[{"name":"Neurology Unit, Department of Systems Medicine Tor Vergata University  Rome Italy"},{"name":"IRCCS Neuromed  Pozzilli Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi Francesco","family":"Iannone","sequence":"additional","affiliation":[{"name":"Department of Biomedical, Metabolic and Neural Sciences University of Modena and Reggio Emilia  Modena Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"key":"e_1_2_12_2_1","unstructured":"World Health Organization.Global status report on neurology.https:\/\/www.who.int\/publications\/i\/item\/9789240116139"},{"issue":"2","key":"e_1_2_12_3_1","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41582-022-00763-1","article-title":"Global epidemiology of migraine and its implications for public health and health policy","volume":"19","author":"Steiner TJ","year":"2023","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"e_1_2_12_4_1","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/S2468-2667(24)00302-5","article-title":"Global, regional, and national burden of epilepsy, 1990\u20132021: a systematic analysis for the global burden of disease study 2021","volume":"10","author":"Feigin VL","year":"2025","journal-title":"Lancet Public Health"},{"issue":"9","key":"e_1_2_12_5_1","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41582-021-00516-6","article-title":"Headache in people with epilepsy","volume":"17","author":"Bauer PR","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"e_1_2_12_6_1","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1649543","article-title":"Epilepsy and migraine: a diagnostic and therapeutic challenge","volume":"16","author":"Pascarella A","year":"2025","journal-title":"Front Pharmacol"},{"issue":"4","key":"e_1_2_12_7_1","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.tips.2007.02.005","article-title":"Antiepileptic drugs in migraine: from clinical aspects to cellular mechanisms","volume":"28","author":"Calabresi P","year":"2007","journal-title":"Trends Pharmacol Sci"},{"issue":"8","key":"e_1_2_12_8_1","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2174\/1570159X21666221228095256","article-title":"Antiseizure medications for the prophylaxis of migraine during the anti\u2010CGRP drugs era","volume":"21","author":"Rollo E","year":"2022","journal-title":"Curr Neuropharmacol"},{"key":"e_1_2_12_9_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2023.109093","article-title":"Treatment of benzodiazepine\u2010refractory status epilepticus: a retrospective, cohort study","volume":"140","author":"Rollo E","year":"2023","journal-title":"Epilepsy Behav"},{"issue":"2","key":"e_1_2_12_10_1","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1152\/physrev.00059.2021","article-title":"CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond","volume":"103","author":"Russo AF","year":"2023","journal-title":"Physiol Rev"},{"issue":"2","key":"e_1_2_12_11_1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/bcp.12618","article-title":"CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment","volume":"80","author":"Edvinsson L","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_12_12_1","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.peptides.2013.04.001","article-title":"Role of alpha\u2010CGRP in the regulation of neurotoxic responses induced by kainic acid in mice","volume":"44","author":"Park SH","year":"2013","journal-title":"Peptides"},{"issue":"3","key":"e_1_2_12_13_1","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0167-0115(89)90189-4","article-title":"Pronounced increases in brain levels of calcitonin gene\u2010related peptide after kainic acid induced seizures","volume":"26","author":"Saria A","year":"1989","journal-title":"Regul Pept"},{"issue":"8","key":"e_1_2_12_14_1","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1111\/head.13591","article-title":"CGRP and brain functioning: cautions for migraine treatment","volume":"59","author":"Borkum JM","year":"2019","journal-title":"Headache"},{"issue":"2","key":"e_1_2_12_15_1","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/epi.17147","article-title":"Not your usual drug\u2010drug interactions: monoclonal antibody\u2013based therapeutics may interact with antiseizure medications","volume":"63","author":"Berman E","year":"2022","journal-title":"Epilepsia"},{"issue":"10483","key":"e_1_2_12_16_1","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/S0140-6736(25)00109-6","article-title":"Calcitonin gene\u2010related peptide\u2010targeted therapy in migraine: current role and future perspectives","volume":"405","author":"Versijpt J","year":"2025","journal-title":"Lancet"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/epi.70436"},{"issue":"2","key":"e_1_2_12_18_1","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/head.14903","article-title":"Pharmacological differences and switching among anti\u2010CGRP monoclonal antibodies: a narrative review","volume":"65","author":"Romozzi M","year":"2025","journal-title":"Headache"},{"issue":"12","key":"e_1_2_12_19_1","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s40263-025-01235-y","article-title":"Effect of Atogepant on sleep quality and sleep\u2010related adverse events in adult patients with migraine: a prospective observational 12\u2010week study","volume":"39","author":"Iannone LF","year":"2025","journal-title":"CNS Drugs"}],"container-title":["Epilepsia Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/epi4.70364","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/epi4.70364","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/epi4.70364","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:42:39Z","timestamp":1791560559000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/epi4.70364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":18,"alternative-id":["10.1002\/epi4.70364"],"URL":"https:\/\/doi.org\/10.1002\/epi4.70364","archive":["Portico"],"relation":{},"ISSN":["2470-9239","2470-9239"],"issn-type":[{"value":"2470-9239","type":"print"},{"value":"2470-9239","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"assertion":[{"value":"2026-07-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"epi4.70364"}}